Achieving Clinical Success with Pulmonary Delivery for Biologics
Pulmonary delivery for biologics is transforming drug development by enabling targeted, patient-friendly therapies. This webinar, “Charting the Course for Clinical Trials: A Guide to Success,” explores how Aptar Pharma, Nanopharm, and PULMOTREE are working together by combining innovative device platforms and advanced analytical tools to accelerate clinical development. Attendees will discover strategies for optimizing formulation, device compatibility, and patient outcomes, supporting regulatory success and faster market access for inhaled biologic therapies.
Charting the Course for Clinical Trials: A Guide to Success
By: Jonathan Mulpas, Carolina Dantas, Will Ganley
The webinar spotlights the expanding role of pulmonary delivery for biologics, a strategy that is reshaping the landscape of respiratory and systemic therapies. By enabling targeted, non-invasive administration, pulmonary delivery empowers patients and supports the development of next-generation biologic treatments. The session, “Charting the Course for Clinical Trials: A Guide to Success,” brings together Aptar Pharma, Nanopharm, and PULMOTREE to demonstrate how innovative device platforms and integrated analytics can accelerate clinical development.
Despite its promise, the path to successful pulmonary delivery for biologics is complex. The webinar addresses scientific and regulatory challenges, including formulation stability, device compatibility, and the need to ensure consistent therapeutic outcomes across diverse patient populations. Attendees gain insights into the multifactorial nature of OIPD (Orally Inhaled and Nasal Drug Product) efficacy, highlighting the importance of robust characterization and predictive modeling throughout development.
Serving as an educational forum, the webinar introduces advanced technologies such as the Kolibri Mesh Nebulizer and Nanopharm’s SmartTrack® platform. These tools, alongside comprehensive characterization and formulation services, streamline the selection of optimal device-formulation combinations. The session also features Simhalation™, Nanopharm’s in-house PBPK modeling tool, which enables simulation of drug deposition and absorption, supporting data-driven decisions and regulatory submissions.
Real-world case studies are presented to illustrate the practical application of these integrated solutions. Participants see how leveraging hands-on device interaction, in-vitro and in-silico testing, and patient-centric design can reduce development timelines and enhance the likelihood of clinical and commercial success for inhaled biologic therapies.
Finally, the webinar highlights Aptar Pharma’s and PULMOTREE’s collaborative approach in supporting pharmaceutical companies at every stage of development. Their combined expertise and innovative platforms help navigate the complexities of pulmonary biologic delivery, empowering teams to bring transformative therapies to patients efficiently and effectively.
